Report Highlights

Smart Exoskeletons in the U.S.: Market Overview

The U.S. smart exoskeleton market was valued at USD 0.42 billion in 2024 and is forecast to reach USD 1.19 billion by 2032, growing at a 13.9% CAGR. The market divides into clinical rehabilitation devices, which must obtain FDA clearance under 21 CFR 890.3480, and industrial and defence exoskeletons, which largely operate outside the medical device pathway. Government procurement through Army Combat Capabilities Development Command Soldier Center evaluations seeded early demand, while private firms such as Ekso Bionics and Parker Hannifin's Indego line commercialised clinical systems.

Policy has shaped the market's current form more than private investment has. The Federal Food, Drug, and Cosmetic Act's 510(k) pathway determined which products reached hospitals, and Medicare Part B coverage under the DMEPOS benefit set the reimbursement envelope for home use. Private leadership is strongest in industrial wearables, where Hyundai's VEX and Ottobock's Paexo compete on price and ergonomic performance without equivalent federal gatekeeping.

Policy-Driven Growth in U.S. Smart Exoskeletons

Medicare Part B pays 80 percent of the Medicare-allowed amount for covered durable medical equipment after the annual deductible, enabling FDA-cleared powered exoskeletons for spinal cord injury to reach patients at home. The mechanism works because coverage converts a one-time capital purchase into a recurring reimbursable service, shifting demand from hospital budgets to individual beneficiaries. CMS payment rates under the DMEPOS Competitive Bidding Program, governed by 42 CFR Part 414 Subpart F, will determine how much of that demand remains commercially viable.

The Department of Defense's exoskeleton programmes, administered by the Army's Combat Capabilities Development Command Soldier Center in Natick, Massachusetts, create a federal demand signal for load-carrying systems. Awards are governed by the Buy American Act and the Berry Amendment codified at 10 U.S.C. 4862, which channel contracts toward domestic suppliers. The Veterans Health Administration's Prosthetic and Sensory Aids Service adds a second channel by procuring powered orthoses for veterans, converting federal health budgets into predictable volume that lowers unit costs.

Regulatory Barriers and Compliance Costs

Powered lower-extremity exoskeletons are Class II devices under 21 CFR 890.3480, requiring 510(k) premarket notification reviewed by the FDA's Center for Devices and Radiological Health. Although the statutory review clock averages about 90 days, substantive interaction commonly extends clearance to six to twelve months. Manufacturers must also comply with the Quality Management System Regulation, effective February 2, 2026, which aligns FDA requirements with ISO 13485 and raises audit and documentation costs for mid-size firms.

Industrial exoskeletons sold for workplace use fall outside FDA oversight but remain subject to Section 5(a)(1) of the Occupational Safety and Health Act, the General Duty Clause enforced by OSHA, which requires employers to control recognised ergonomic hazards. Defence sales must satisfy Buy American Act certifications and supplier audits, adding several months to contract award timelines. Medicare reimbursement requires HCPCS coding and complete DMEPOS documentation before any revenue is recognised, creating administrative costs that smaller manufacturers struggle to absorb.

Policy-Created Opportunities in U.S. Smart Exoskeletons

The Army's exoskeleton evaluation programme and VA procurement through the Prosthetic and Sensory Aids Service create a subsidised demand category for load-carrying and mobility-assist devices. Vendors that hold domestic assembly and Buy American certification can secure multi-year pilot contracts that convert into production orders. This channel favours manufacturers with established federal contracting infrastructure over early-stage device developers.

The FDA Breakthrough Devices Program, established under Section 515B of the Federal Food, Drug, and Cosmetic Act, grants priority interaction with reviewers for devices addressing life-threatening or irreversibly debilitating conditions. CMS's Transitional Coverage for Emerging Technologies pathway allows breakthrough-designated devices to receive temporary Medicare coverage while evidence accumulates. Together these mechanisms shorten the route from clearance to reimbursed patient access for neurologically focused exoskeletons.

Market at a Glance

Leading Market Participants

• Ekso Bionics
• Lifeward (ReWalk Robotics)
• Parker Hannifin
• Lockheed Martin
• Roam Robotics
• U.S. Bionics (suitX)
• Myomo
• Hyundai Motor Group
• Ottobock
• Sarcos Technology and Robotics

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the FDA's Center for Devices and Radiological Health, which classifies powered exoskeletons under 21 CFR 890.3480. Key compliance requirements include 510(k) premarket notification, the Quality Management System Regulation effective February 2, 2026, and medical device reporting. Reimbursement is governed by Title XVIII of the Social Security Act and 42 CFR Part 414 Subpart F, while workplace devices fall under the Occupational Safety and Health Act of 1970.

Compared with regional peers, the U.S. framework is faster to market than the European Union's Medical Device Regulation (Regulation (EU) 2017/745), which requires notified-body certification for Class IIa and IIb devices. Japan's Pharmaceuticals and Medical Devices Act permitted Cyberdyne's HAL system to reach clinical use earlier, but U.S. Medicare coverage offers broader reimbursement scale. The next material change is the QMSR transition in 2026, followed by future DMEPOS competitive bidding rounds that will reset payment rates.

Long-Term Policy Outlook for U.S. Smart Exoskeletons

By 2032, competitive bidding under 42 CFR Part 414 Subpart F will likely be the decisive price-setting mechanism for home-use exoskeletons, favouring lower-cost pneumatic and soft systems over rigid frames. Expanded Breakthrough Devices designations and TCET coverage will support earlier reimbursed access for neurological indications. Manufacturers that complete QMSR alignment before February 2026 will avoid post-transition audit backlogs.

Defence procurement will remain the largest policy-driven volume source through the Army's Soldier Center programmes and Buy American Act enforcement, which will reward domestic assembly. Workplace exoskeletons will face growing OSHA ergonomic scrutiny, creating demand for certified industrial systems. Firms that align clinical, defence, and industrial compliance pathways will capture the most durable share of the market by 2032.